| Item type |
文献 / Documents(1) |
| 公開日 |
2020-12-09 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/cas.13772 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1111/cas.13772 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer : A phase II study |
|
言語 |
en |
| 著者 |
オオヌマ, ヒロユキ
佐藤, 康史
ハヤサカ, ナオタカ
マツノ, テッペイ
フジタ, チサ
サトウ, マサノリ
オオスガ, タカヒロ
ヒラカワ, マサヒロ
ミヤニシ, コウジ
サガワ, タモツ
フジカワ, コウシ
オオイ, モトオ
オカガワ, ユタカ
ツジ, ヤスシ
ヒラヤマ, ミチアキ
イトウ, タツヤ
ノブオカ, タカユキ
タケマサ, イチロウ
コブネ, マサヨシ
カトウ, ジュンジ
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Cisplatin plus 5‐fluorouracil is regarded as standard neoadjuvant chemotherapy for esophageal squamous cell carcinoma (ESCC) in Japan, but the prognosis remains poor. We have previously described how definitive chemoradiotherapy with docetaxel, nedaplatin, and 5‐fluorouracil (DNF) led to a very high response rate and promising survival times. We therefore undertook a phase II trial to evaluate the feasibility and efficacy of neoadjuvant DNF. The study included patients with clinical stage Ib‐III ESCC. Chemotherapy consisted of i.v. docetaxel (30 mg/m2) and nedaplatin (50 mg/m2) on days 1 and 8, and a continuous infusion of 5‐fluorouracil (400 mg/m2/day) on days 1‐5 and 8‐12, every 3 weeks. After three courses of chemotherapy, esophagectomy was carried out. The primary end‐point was the completion rate of the protocol treatment. Twenty‐eight patients were enrolled (cStage Ib/II/III, 2/3/23) and all received at least two cycles of chemotherapy. Twenty‐five patients underwent surgery, all of whom achieved an R0 resection, leading to a completion rate of 89.3%. The overall response rate was 87.0%. A pathological complete response was confirmed in eight (32.0%) cases. Grade 3/4 adverse events included leukopenia (32.1%), neutropenia (39.3%), febrile neutropenia (10.7%), thrombocytopenia (10.7%), and diarrhea (14.3%), but were manageable. Treatment‐related deaths and major surgical complications did not occur. Estimated 2‐year progression‐free and overall survival rates were 70.4% and 77.2%, respectively. Thus, DNF therapy was well tolerated and deemed feasible, with a strong tumor response in a neoadjuvant setting for ESCC. This trial is registered with the University Hospital Medical Information Network (UMIN ID: 000014305). |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
docetaxel |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
esophageal cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
esophageal squamous cell carcinoma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
nedaplatin |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
neoadjuvant chemotherapy |
| 書誌情報 |
en : Cancer Science
巻 109,
号 11,
p. 3554-3563,
発行日 2018-08-23
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13497006 |
| 出版者 |
|
|
出版者 |
Japanese Cancer Association |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
John Wiley & Sons |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| EID |
|
|
識別子 |
345436 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
cas_109_11_3554.pdf (248 KB)
.png)
